Community seroprevalence of COVID-19 in probable and possible cases at primary health care centres in Spain

Montenegro, Patricia; Brotons, Carlos; Serrano, Jordi; Fernández, Diana; Garcia-Ramos, C; Ichazo, Begoña; Lemaire, Jeannine; Moral, Irene; Wienese, R Pérez; Pitarch, Marc; Puig, Mireia; Vilella, MT; Sellarés, Jaume

doi:10.1093/fampra/cmaa096

Cited by 20 publications

(19 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Asymptomatic individuals from the randomly selected sample participated in a Spanish study investigated COVID-19 IgG and/or IgM and the prevalence was found as 5.47% [ 40 ]. The seroprevalence of SARS-CoV-2 IgG and/or IgM antibody in asymptomatic individuals was found to be 2.39% in Wuhan [ 41 ].…”

Section: Discussionmentioning

confidence: 99%

Facial paralysis as the only symptom of COVID-19: A prospective study

İslamoğlu

Çelik

Kırış

2021

American Journal of Otolaryngology

View full text Add to dashboard Cite

Purpose Idiopathic facial palsy is called as Bell's palsy and reports showed that facial paralysis increased during COVID-19 pandemic period. There are many reports about the relationship between COVID-19 and facial paralysis but there is no prospective study. SARS-CoV-2 IgG and IgM antibodies increase in COVID-19. Our purpose is to investigate SARS-CoV-2 IgG + IgM antibody in the Bell's palsy. Methods Prospective cross-sectional study was planned. Patients with acute peripheral facial paralysis with no reason and diagnosed as Bell's palsy was included in the study. In order to investigate SARS-CoV-2 in the etiologies of these patients, SARS-CoV-2 IgM + IgG (total) test was studied. SARS-CoV-2 IgG + IgM was measured by using the ADVIA Centaur® test kit. Test reports result in index values and as nonreactive or reactive. The results were analyzed. Results Forty-one patients were included in the study. The average age of the patients was 41,7. 17 (41,4%) were female and 24 (58,6%) were male. 21 patients had left-sided; 20 had right-sided paralysis. SARS-CoV-2 IgG + IgM values were measured two times of the patients. First control was in the first week of facial paralysis, 10 (24,3%) positivity was found. The average index of the positive patients were 6,74 (min.1,39–max.10) in the first control and 9,585 in the second control (min.8,7–max. 10). Conclusion We found that the SARS-CoV-2 IgM + IgG antibody test was positive in 24.3% of the patients with Bell's palsy. The results are higher than the seroprevalence studies conducted in asymptomatic individuals. Facial paralysis could be the only symptom of COVID-19 but further studies must be done.

show abstract

Section: Discussionmentioning

confidence: 99%

Facial paralysis as the only symptom of COVID-19: A prospective study

İslamoğlu

Çelik

Kırış

2021

American Journal of Otolaryngology

View full text Add to dashboard Cite

show abstract

“…There are no seroprevalence data from community healthcare settings in Ireland available, and indeed little internationally, but data are available from Spain where a seroprevalence rate of 5.5-5.9% has been demonstrated [45][46] . Our study makes a valuable contribution to our knowledge regarding potential levels of circulating SARs-CoV2 in such settings in Ireland and our methodology may assist future similar studies in Irish general practice.…”

Section: Comparison With Existing Literaturementioning

confidence: 99%

SARS-CoV-2 infection in general practice in Ireland: a seroprevalence study

et al. 2021

View full text Add to dashboard Cite

Background: SARS-CoV-2 antibody testing in community settings may help us better understand the immune response to this virus and therefore help guide public health efforts. Aim: Conduct a seroprevalence study of IgG antibodies in Irish GP clinics. Design and Setting: Participants were 172 staff and 799 patients of 15 general practices in the Midwest region of Ireland. Methods: This seroprevalence study utilised 2 manufacturers’ point-of-care (POC) SARS-CoV-2 IgM-IgG combined antibody tests, offered to patients and staff in general practice from mid-June to mid-July 2020. Results: Immunoglobulin G (IgG) seroprevalence was 12.6% in patients attending general practice and 11.1% in staff working in general practice, with administrative staff having the lowest seroprevalence at 2.5% and nursing staff having the highest at 17.6%. Previous symptoms suggestive of SARS-CoV-2 and history of a polymerase chain reaction (PCR) test were associated with higher seroprevalence. IgG antibodies were detected in approximately 80% of participants who had a previous PCR-confirmed infection. Average length of time between participants’ positive PCR test and positive IgG antibody test was 83 days. Conclusion: Patients and healthcare staff in general practice in Ireland had relatively high rates of IgG to SARS-CoV-2 compared to the national average at the time (1.7%). Four-fifths of participants with a history of confirmed COVID-19 disease still had detectable antibodies an average of 12 weeks post-infection. While not proof of immunity, SARS-CoV-2 POC testing can be used to estimate IgG seroprevalence in general practice settings.

show abstract

“…Asymptomatic individuals from the randomly selected sample participated in a Spanish study investigating COVID-19 IgG and/or IgM and the prevalence found was 5.47% 24 .…”

Section: Resultsmentioning

confidence: 99%

Evidence for facial nerve palsy and SARS-CoV-2

Teles

Carneiro²,

Pestana³

2021

Rev Neurocienc

View full text Add to dashboard Cite

Introduction. The World Health Organization (WHO) has recognized a new strain of coronavirus, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), called Coronavirus Disease 2019 (COVID-19). The mildest and most common symptoms include fever, fatigue and cough; however, more severe cases of the disease can cause breathing difficulties, kidney and heart failure and, eventually, death. However, an increasing number of reports of neurological manifestations have emerged. Objective. Provide a comprehensive review of the neurological manifestations of SARS-CoV-2 and especially the relationship between acute facial nerve palsy and COVID-19, as well as their results in mortality and the implications that this has in clinical practice. Method. The search in seven databases (PubMed, Cochrane Library, Lilacs, Scielo, Web of Science, Scopus and Google Scholar) was carried out by two independent reviewers in search of evidence of Facial Nerve Palsy (VII) and SARS-CoV-2 . After screening, data were collected and discussed. Results. Idiopathic facial palsy is called Bell's palsy and studies have shown that facial palsy increased during the COVID-19 pandemic period. There are many reports on the relationship between COVID-19 and facial paralysis, but little real evidence of their relationship. Conclusion. It is still questionable whether these neuroimmune disorders occur directly from viral infection or as autoimmune sequelae. The pathogenesis of the disease behind this manifestation is not yet fully understood. We believe that more research should be carried out to clarify the association raised by this study.

show abstract

Community seroprevalence of COVID-19 in probable and possible cases at primary health care centres in Spain

Cited by 20 publications

References 7 publications

Facial paralysis as the only symptom of COVID-19: A prospective study

Facial paralysis as the only symptom of COVID-19: A prospective study

SARS-CoV-2 infection in general practice in Ireland: a seroprevalence study

Evidence for facial nerve palsy and SARS-CoV-2

Contact Info

Product

Resources

About